Today’s AI Top Pick: AZN

7/28/2026 · AI Conviction screen · a free sample of K3vl4r’s AI-curated picks.

AI-ranked from a screened shortlist, with entry strategy, targets, and risks.

Measured daily model accuracy · AZN66%338 resolved forecasts · 45d window · verify →

Today's pick · AI ConvictionAZNBUY NOW8.6 / 107/28/2026

AstraZeneca is the cleanest setup on the board today: strong analyst conviction (fundamental_score 7, recom 1.68, targetUpsidePct 26.6%), Kronos bullish_prob of 1.0 with near_term_bullish 0.8, and — crucially — a genuine positive catalyst that just landed. AZN reported Q2 on 2026-07-27 with a $2.63 EPS beat and reaffirmed the $80B revenue target, backed by strong oncology/rare disease growth. That is exactly the kind of fundamental confirmation you want under a bullish forecast tape. The forecast alignment on the actionable timeframes is unusually tight for a name this depressed. 1h projects +10.23% short / +9.22% mid / +6.80% long; 4h projects +9.19% / +9.32% / +9.45%; the daily still points up (+2.22% / +5.92% / +2.71%). Multi-timeframe agreement on the 1h/4h/1d is the 'gold' scenario the brief calls for. Yes, the 1wk lens is negative (-5.7/-19.4/-19.4), but that is the classic post-selloff mean-reversion shape — the weekly is anchored to the pre-earnings decline, not the fresh beat. Entry quality is the differentiator versus the other bullish_prob=1 names. AZN is at pos_in_21bar_range_pct of just 1.85% (4h) and 18.6% (1d), with drawdowns of -12.75% (4h) and -12.79% (1d) from the 21-bar high. RSI 42.55 — not oversold, but firmly not extended. Contrast this with MSFT (1h pos 97%, at prior high), MELI (4h/1d pos 80-100%), ROP (1d pos 100%), and MMSI (1wk pos 100%): every other bullish_prob=1 name requires you to chase. AZN lets you buy the dip with the model, the analyst, and the earnings print all aligned. Why today and not later: the tape says the rebound starts in the short/mid window (1h and 4h forecasts are front-loaded at +9-10%), so waiting for a further pullback risks missing the snap-back. The stop is well-defined right below the 4h low, and the risk/reward against a 26.6% analyst upside plus a fresh earnings beat is asymmetric.

Entry zone

$169.50–$171.00 (current $170.20; scale in on any dip toward $168 which is near the 4h 21-bar low)

Stop loss

$164.50 (below the ~-12.8% 21-bar drawdown low; ~3.3% risk from entry)

First target

$182–$185 (aligns with 1h/4h forecasts of +7-9% and reclaim of pre-earnings level)

Longer target

$200–$210 (analyst targetUpside of 26.6% off current, consistent with $80B revenue thesis and PEG 1.23 with fwdPE 14.68)

Risks

1wk forecast is materially negative (-5.7% / -19.4% / -19.4%), signaling the bigger-timeframe downtrend hasn't turned — this is a bounce trade, not a breakout trade
Position at just 1.85% of 4h range and 3.62% of 1wk range means the stock is still in a defined downtrend; a break below $164 invalidates the mean-reversion thesis
Pharma sector headline risk (pricing, IRA drug negotiation, regulatory) can override technicals — profitMargin 17.19% but debtEq 0.72 leaves less cushion than pure-play large caps
FX/ADR risk given AZN is UK-listed; a stronger USD or GBP move can amplify moves against the thesis
Post-earnings drift can go either way — if the +$2.63 beat is already 'priced in,' the 1wk model's negative view could dominate and the bounce fades quickly

Honorable mentions

MSFTbullish_prob 1.0, fundamental_score 8, and the 1d forecast is very strong (+11.95% mid, +17% long). Downside is entry quality — 1h at pos 97% means you're buying at the immediate high, and the 1wk forecast is -4 to -5%. Better on a pullback to the low $380s.

MELIbullish_prob 1.0, near_term 0.6, all four timeframes' recent moves are positive and 1d forecast is +11.28% mid / +11.79% long with 42% salesYoY. Held back only because pos_in_21bar_range is 100% on 4h and 80%+ on 1d — you're chasing. BUY_PULLBACK toward $1,780.

Full ranking (30)

#	Symbol	Verdict	Score	Read
1	AZN	BUY NOW	8.6	Post-earnings-beat dip with prob=1.0, near_term=0.8, and 1h/4h forecasts of +9-10% while sitting at just 1.85% of 4h range.
2	MSFT	BUY PULLBACK	7.6	Prob=1.0 and 1d forecast +17% long, but 1h pos_in_range 97% — wait for a dip to sub-$385.
3	MELI	BUY PULLBACK	7.2	Prob=1.0, 1d forecast +11%, 42% sales growth, but at 100% of 4h range — chase risk.
4	FOX	BUY NOW	6.8	Prob=1.0, near_term 0.8, all short/mid/long positive on 1h/4h/1d, fwdPE 8.72 with 40% analyst upside.
5	ROP	BUY PULLBACK	6.5	Prob=1.0, 1wk forecast +23% long, but 1d and 1wk both at pos 100% — needs a pullback.
6	MMSI	BUY PULLBACK	6.0	Prob=1.0, 1d forecast mildly positive, but 1wk at pos 100% and 1h/4h short-term forecasts negative.
7	PRGS	BUY PULLBACK	5.7	Prob 0.4, but 1d/1wk forecasts strongly positive (+24% mid on weekly) and fwdPE 6.16 — 1h forecast -26% argues for waiting.
8	MRP	WAIT	5.4	fundamental_score 8, recom 1.0, but no bullish_prob and mid-timeframe forecasts only modestly positive.
9	PCTY	WAIT	4.8	Fundamentals score 7 but at pos 100% on 4h/1d/1wk with 1h/4h/1d forecasts sharply negative (-22% short).
10	WCN	WAIT	4.5	near_term 0.8 but forecasts modestly negative across horizons and pos 100% on 1wk.
11	MDLN	WAIT	4.3	Only 1d data; recall headline is a negative catalyst — Medline recall in July.
12	SKM	WAIT	4.2	Massive Nvidia $500B AI infrastructure deal is a real catalyst, but 1d/1wk model forecasts are deeply negative (-22 to -29%).
13	RELY	WAIT	4.0	PEG 0.49 and analyst recom 1.08 attractive, but prob=0 and 1d/1wk forecasts sharply negative (-24%/-15%).
14	NVT	WAIT	3.8	Prob=0, near_term 0.2; 1d/1wk forecasts brutal (-37% and -60% long) despite fundamental_score 7.75.
15	APH	WAIT	3.5	Earnings tomorrow — pos_in_range 0% on daily and prob=0; wait for the print.
16	SKWD	AVOID	3.4	Prob=0 and 1wk forecast -32.7% long; buyback expansion insufficient to override forecast.
17	PRG	AVOID	3.0	Prob=0, 1h/4h/1d forecasts uniformly negative (-15 to -28%), at 52-week high risk of exhaustion.
18	URI	AVOID	3.0	Prob=0, 1wk forecast -48% long, CFO selling into strength — clear top signal.
19	RGA	AVOID	2.9	Prob=0, near_term=0, all forecasts negative from 1h to 1wk (-13 to -25%).
20	TDY	AVOID	2.7	Prob=0, 1wk forecast -34% long, PEG 2.67, only 15.9% analyst upside.
21	NVS	AVOID	2.5	Prob=0, targetUpside -1.4%, PEG 2.4, all forecasts negative.
22	WM	AVOID	2.5	Prob=0, forecasts uniformly negative, PEG 2.62, only 8.9% upside.
23	RTX	AVOID	2.4	RSI 77.31 severely overbought, at 52-week high, 1wk forecast -55% mid — classic blow-off setup.
24	NTAP	AVOID	2.3	Prob=0 with 1d forecast -35% and 1wk -40%; targetUpside only 4.4%.
25	OSW	AVOID	2.2	Prob=0, 1wk forecast -40% long, insider fund sold at intrinsic value per recent news.
26	MYE	AVOID	1.8	Prob=0, 1wk forecast -47% across horizons; +115% YoY move looks exhausted.
27	PRLB	AVOID	1.6	Prob=0, PE 73, 1d forecast -36% short, PEG null — pure momentum unwind risk.
28	MTRN	AVOID	1.4	Prob=0, 1d forecast -40% short/-49% mid, at 21-bar low with continued downside modeled.
29	WELL	AVOID	1.3	Fundamental_score -1.75, fwdPE 76, targetUpside -0.5%, forecasts strongly negative despite earnings beat.
30	BBC	AVOID	1.0	ETF with no fundamentals and no forecast tape provided — nothing actionable here today.

Get AI top picks & forecasts on any stock

K3vl4r screens the market daily and ranks the best setups with AI — forecasts, scored fundamentals & technicals, and multi-horizon price targets. Create a free account to explore them all.

Create your free account →

Already a member? Sign in · Join our Discord